GEN Exclusives

More »

GEN News Highlights

More »
Feb 9, 2012

IDT Buys 1st Base Custom Oligo Business to Serve Clients in Asia

  • Integrated DNA Technologies (IDT) acquired 1st Base’s oligonucleotide business in Singapore. IDT is renaming the business 1st Base Custom Oligos (FBCO). The 1st Base brand will also be retained for small-scale DNA oligos manufactured at the plant.

    IDT says the acquisition will provide it with its first synthesis facility in Asia, for providing locally manufactured custom oligonucleotides and services  to researchers in Singapore and throughout the region. FBCO will offer DNA and RNA synthesis, oligonucleotide modification, qPCR assays and probes, RNAi synthesis, and gene synthesis products and services.

    “We’re just getting started in Asia, and we have a lot to learn about the needs of the researchers working here,” comments Joseph Walder, Ph.D., IDT founder and CEO. "But with FBCO up and running, and with the support of our new colleagues from 1st Base, we aim to build on IDT’s success in North America and in Europe.”

    IDT provides custom DNA and RNA oligonucleotides and genes to academic, government, and commercial clinets in the biotech, clinical diagnostics, and pharmaceuticals sectors. The firm claims to synthesize and ship an average of 36,000 oligos per day. The firm already operates manufacturing facilities on Iowa, California, and Belgium.

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Easing Restrictions for Terminal Patients

Should the Federal Government Pass a “Right to Try” Bill Allowing Terminally Ill Patients Access to Experimental Medicines?

More »